Survival in XXXX .

@entity1 @entity644 @entity8 @entity101 @entity177 @entity1011 @entity1985 @entity8157
Sixty-seven @entity1 with @entity8157 ( @entity8157 ) were analyzed clinically. Their mean age was 39.3 years, and 47 (70%) of them were male. Fifty (74.6%) showed @entity1985 ( @entity1985 ) initially and five (7.5%) had additionally chronic @entity177 . @entity101 was present in 27%. During the follow-up (mean 6.7 years) @entity8 occurred in four @entity1 12-151 (mean 84.2) months after the diagnosis of @entity8157 . Four @entity1 died of non-renal causes. The actuarial life-table survival at 5, 10 and 15 years was 94%, 83% and 69%, respectively. To some extent renal function deteriorated in 13 @entity1 (19%). These @entity1 were older (49.9 vs. 36.8 years, p less than 0.01) than those with preserved renal function, and many of them had serum @entity1011 levels of 125 mumol/l or more initially. Sex did not correlate with the development of @entity177 . @entity1 with slight @entity644 never showed @entity177 . The retrospective comparison of survival in @entity1 who did (N = 31) or did not (N = 19) receive corticosteroids and/or immunosuppressive drugs for the treatment of @entity1985 revealed no evident difference at 5 or 10 years. This clinical analysis emphasizes the fairly favorable outcome of @entity1 with @entity8157 . Hence a reserved view must be taken when treatment with potentially dangerous agents is considered in a disease with unknown etiology and pathogenesis.
